Evidence map›Paper›PMID 36320410›Full record

ArticleMolecular therapy. Methods & clinical development2022

NCS1 overexpression restored mitochondrial activity and behavioral alterations in a zebrafish model of Wolfram syndrome.

Lucie Crouzier, Elodie M Richard, Camille Diez, Morgane Denus, Amandine Peyrel, Hala Alzaeem, Nicolas Cubedo, Thomas Delaunay, Tangui Maurice, Benjamin Delprat

Abstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Novel in vivo models of autosomal optic atrophy reveal conserved pathological changes in neuronal mitochondrial structure and function.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  3. Article
  4. Review
  5. Review
  6. Wfs1Cell death & disease · 2023
    Article
  7. Use of Zebrafish Models to Boost Research in Rare Genetic Diseases.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lucie CrouzierMMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France.
Elodie M RichardMMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France.
Camille DiezMMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France.
Morgane DenusMMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France.
Amandine PeyrelMMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France.
Hala AlzaeemMMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France.
Nicolas CubedoMMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France.
Thomas DelaunayIES, University Montpellier, CNRS, Montpellier, France.
Tangui MauriceMMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France.
Benjamin DelpratMMDN, Univ Montpellier, EPHE, INSERM, Montpellier, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Wolfram syndrome (WS) is a rare neurodegenerative disease resulting in deafness, optic atrophy, diabetes, and neurological disorders. Currently, no treatment is available for patients. The mutated gene,

Indexed as

endoplasmic reticulum stressmitochondriaNCS1Wolfram syndromezebrafish larvae

Identifiers

PMID36320410
PMCPMC9594121

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.